Exacta™ is a comprehensive genomic test designed to identify key genetic alterations and pathways driving the cancer, enabling us to understand which treatments might work best against it. It is a multi-analyte and multi-coordinate investigation that integrates genomic alterations in 500+ genes and perturbations in the expressions of 20,802 genes to unravel actionable mutations and pathways propelling cancer. Exacta™ can identify the most efficacious drugs for every individual cancer and thus enable highly sophisticated treatment strategies beyond the conventional perspective, even for difficult refractory cancers.
Turning Tumor Data into Treatment Strategy
Ranks treatments based on predicted efficacy and tolerability, not just presence of mutations
Interprets alterations within tumor-wide signalling networks, not in isolation
Reduces uncertainty by combining molecular data with functional validation
Identifies viable strategies even when conventional options are exhausted
Moving from Mutation Detection to Treatment Design
Maps interactions between genes, pathways, and tumor behaviour
Captures not just what is altered, but how those alterations influence disease progression
Tests real tumor response to drugs to validate molecular predictions
Selects optimal drug combinations balancing efficacy and toxicity
Designed for Real-World Oncology Challenges
Supports treatment planning in biologically aggressive cancers
Explains lack of response by identifying hidden resistance mechanisms
Guides next-line therapy after relapse or progression
Differentiates between potentially effective and ineffective cytotoxic drugs
Identifies synergistic drug combinations for improved outcomes
A 360° Molecular and Functional Assessment of Cancer
Deep Tumor Interrogation at Source
Non-Invasive Systemic Tumor Profiling
A tumor’s behaviour cannot always be predicted by DNA mutations alone. Exacta™ addresses this gap by combining: What is altered (genomics), what is active (transcriptomics), and what actually works (functional testing)? This integrated approach helps: Avoid ineffective treatments, reduce trial-and-error in therapy selection, and improve likelihood of response in advanced settings.
Collection of blood and/or tumor tissue depending on clinical context
Parallel evaluation of genetic, transcriptional, and functional data
Computational modelling of tumor behaviour and vulnerabilities
Alignment of tumor weaknesses with available treatment options
Clear, ranked recommendations for personalized treatment planning